What common mutations and rearrangements--among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS-- present in tumors represent the best molecular targets for cancer therapy?

What common mutations and rearrangements--among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS-- present in tumors represent the best molecular targets for cancer therapy?

What common mutations and rearrangements—among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS— present in tumors represent the best molecular targets for cancer therapy? Are some more predictive of success with targeted therapy than others? Why?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

Professor of Medical Oncology
Director, Yonsei Song-Dang Institute for Cancer Research
Yonsei University College of Medicine
Seoul, Korea